S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital

BridgeBio Pharma (BBIO) Stock Forecast, Price & News

$13.75
+0.21 (+1.55%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$13.22
$13.81
50-Day Range
$12.84
$17.56
52-Week Range
$5.74
$19.94
Volume
1.41 million shs
Average Volume
2.59 million shs
Market Capitalization
$2.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.63

BridgeBio Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
93.6% Upside
$26.63 Price Target
Short Interest
Healthy
11.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
1.06mentions of BridgeBio Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.38) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.86 out of 5 stars

Medical Sector

40th out of 1,010 stocks

Pharmaceutical Preparations Industry

15th out of 494 stocks


BBIO stock logo

About BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Stock News Headlines

Your Ultimate Investment Research Platform
MarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more.
BridgeBio Pharma (NASDAQ:BBIO) Trading Up 6.7%
Your Ultimate Investment Research Platform
MarketBeat All-Access is the all-in-one stock research solution that saves you time and helps you make more money. You get our top stock picks, best-in-class research tools, proprietary research reports and much more.
Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO)
SVB Securities Remains a Buy on BridgeBio Pharma (BBIO)
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $15.15
See More Headlines
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
576
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.63
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+93.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-481,180,000.00
Net Margins
-546.34%
Pretax Margin
-547.77%

Debt

Sales & Book Value

Annual Sales
$77.65 million
Book Value
($7.56) per share

Miscellaneous

Free Float
112,993,000
Market Cap
$2.21 billion
Optionable
Not Optionable
Beta
0.71

Key Executives

  • Neil Kumar
    Chief Executive Officer & Director
  • Jonathan C. Fox
    President & Chief Medical Officer
  • Christine E. Siu
    Chief Operating Officer
  • Brian C. Stephenson
    Chief Financial Officer & Secretary
  • Uma Sinha
    Chief Scientific Officer













BBIO Stock - Frequently Asked Questions

Should I buy or sell BridgeBio Pharma stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BBIO shares.
View BBIO analyst ratings
or view top-rated stocks.

What is BridgeBio Pharma's stock price forecast for 2023?

9 brokerages have issued 12 month target prices for BridgeBio Pharma's shares. Their BBIO share price forecasts range from $18.00 to $40.00. On average, they anticipate the company's stock price to reach $26.63 in the next year. This suggests a possible upside of 93.6% from the stock's current price.
View analysts price targets for BBIO
or view top-rated stocks among Wall Street analysts.

How have BBIO shares performed in 2023?

BridgeBio Pharma's stock was trading at $7.62 at the beginning of 2023. Since then, BBIO shares have increased by 80.4% and is now trading at $13.75.
View the best growth stocks for 2023 here
.

Are investors shorting BridgeBio Pharma?

BridgeBio Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 13,290,000 shares, a decrease of 6.4% from the April 30th total of 14,200,000 shares. Based on an average daily trading volume, of 3,140,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 11.5% of the shares of the stock are sold short.
View BridgeBio Pharma's Short Interest
.

When is BridgeBio Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BBIO earnings forecast
.

How were BridgeBio Pharma's earnings last quarter?

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its earnings results on Thursday, May, 4th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.09. The firm earned $1.83 million during the quarter, compared to analyst estimates of $3.23 million. The business's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.35) earnings per share.

What other stocks do shareholders of BridgeBio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BridgeBio Pharma investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Pfizer (PFE), Roku (ROKU), Editas Medicine (EDIT), Block (SQ), Sorrento Therapeutics (SRNE) and Sarepta Therapeutics (SRPT).

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Hhlr Advisors LTD. (2.48%), Geode Capital Management LLC (1.40%), Perceptive Advisors LLC (1.19%), Pictet Asset Management SA (0.90%), Ensign Peak Advisors Inc (0.67%) and Charles Schwab Investment Management Inc. (0.58%). Insiders that own company stock include Brian C Stephenson, Cameron Turtle, Charles J Homcy, Douglas A Dachille, Genetic Disorder LP Kkr, Michael Thomas Henderson, Neil Kumar, Randal W Scott, Richard H Scheller and Ronald J Daniels.
View institutional ownership trends
.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $13.75.

How much money does BridgeBio Pharma make?

BridgeBio Pharma (NASDAQ:BBIO) has a market capitalization of $2.21 billion and generates $77.65 million in revenue each year. The company earns $-481,180,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How many employees does BridgeBio Pharma have?

The company employs 576 workers across the globe.

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 Kipling Street, Palo Alto CA, 94301. The official website for the company is bridgebio.com. The company can be reached via phone at (650) 391-9740.

This page (NASDAQ:BBIO) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -